Table 1

Demographics and baseline disease characteristics

CLS-TA (N=28)Control (N=5)Total (N=33)
Gender, n (%)
 Male14 (50.0)4 (80.0)18 (54.5)
 Female14 (50.0)1 (20.0)15 (45.5)
Mean (SD) age, years 48.6 (15.04)51.2 (15.82)49.0 (14.93)
Race, n (%)
 Asian20 (71.4)2 (40.0)22 (66.7)
 Black/African American1 (3.6)1 (20.0)2 (6.1)
 White7 (25.0)2 (40.0)9 (27.3)
Anatomic location, n (%)
 Anterior10 (35.7)1 (20.0)11 (33.3)
 Intermediate9 (32.1)0 (0.0)9 (27.3)
 Posterior11 (39.3)1 (20.0)12 (36.4)
 Panuveitis4 (14.3)3 (60.0)7 (21.2)
Aetiology, n (%)
 Idiopathic25 (89.3)3 (60.0)28 (84.8)
 Non-idiopathic3 (10.7)2 (40.0)5 (15.2)*
Onset type, n (%)
 Sudden6 (21.4)1 (20.0)7 (21.2)
 Insidious22 (78.6)4 (80.0)26 (78.8)
Duration, n (%)
 Limited5 (17.9)0 (0.0)5 (15.2)
 Persistent23 (82.1)5 (100)28 (84.8)
Course, n (%)
 Acute1 (3.6)0 (0.0)1 (3.0)
 Recurrent10 (35.7)1 (20.0)11 (33.3)
 Chronic17 (60.7)4 (80.0)21 (63.6)
Presence of ME, n (%)
 Yes28 (100)5 (100)33 (100)
 No0 (0.0)0 (0.0)0 (0.0)
Mean (SD) duration of ME, weeks 46.5 (71.68)106.2 (113.04)55.5 (80.04)
  • *Conditions included sarcoidosis, HLA-B27 related, juvenile idiopathic arthritis, birdshot retinochoroidopathy and pars planitis.

  • CLS-TA, triamcinolone acetonide injectable suspension; ME, macular oedema.